Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accounts Payables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Accounts Payables for 16 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 37.2% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Sep 2025, up 37.2%, and an annual FY2024 reading of $225106.0, down 90.14% over the prior year.
  • Accounts Payables was $2.3 million for Q3 2025 at China Pharma Holdings, up from $530729.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.3 million in Q3 2025 and bottomed at $225106.0 in Q4 2024.
  • Average Accounts Payables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2021.
  • Peak annual rise in Accounts Payables hit 288.08% in 2024, while the deepest fall reached 90.14% in 2024.
  • Year by year, Accounts Payables stood at $327033.0 in 2021, then skyrocketed by 103.98% to $667082.0 in 2022, then soared by 242.19% to $2.3 million in 2023, then plummeted by 90.14% to $225106.0 in 2024, then soared by 923.15% to $2.3 million in 2025.
  • Business Quant data shows Accounts Payables for CPHI at $2.3 million in Q3 2025, $530729.0 in Q2 2025, and $2.2 million in Q1 2025.